Mifepristone Faces New Major Legal Challenge in US Courts

Mifepristone has been FDA-approved since 2000. It has a safety record accumulated over more than two decades and tens of millions of uses globally. It is the most commonly used method of ending a pregnancy in the United States, involved in over half of all abortions performed in the country. And it is, once again, facing a significant legal challenge in American courts that could restrict or eliminate patient access to the medication. The persistence of these legal battles — each resolved or paused only to be replaced by a new case — reflects how thoroughly abortion medication has become a permanent front in the United States' ongoing culture and policy war over reproductive rights.

The Accumulated Legal History of Mifepristone

The sustained legal assault on mifepristone accelerated after the Supreme Court overturned Roe v. Wade in June 2022, which eliminated the constitutional protection for abortion access and sent abortion law back to individual states. Anti-abortion advocacy groups shifted strategy toward federal litigation targeting the FDA's approval process and prescribing rules for mifepristone, reasoning that a nationwide restriction on the drug could achieve what state-by-state legislative battles could not: limiting medication abortion access even in states where abortion remains legal.

The most prominent earlier challenge, Alliance for Hippocratic Medicine v. FDA, worked its way to the Supreme Court, which ruled unanimously in June 2024 that the plaintiffs — a group of anti-abortion physicians — lacked standing to sue because they had not demonstrated a concrete injury from mifepristone's availability. That ruling did not address the merits of whether the FDA's approval decisions were lawful. It only decided that those particular plaintiffs could not bring the case. The legal door was left open for other plaintiffs with different standing arguments to try again.

What the New Challenge Is Targeting

The current legal challenge is attempting to engage different legal theories and different plaintiff configurations that address the standing problem that sank the previous case. The substantive arguments anti-abortion litigants have deployed against mifepristone typically fall into several categories: challenges to the original 2000 FDA approval process under the accelerated pathway that was used; challenges to FDA's 2016 and 2021 expansions of the prescribing rules that extended the gestational age limit and allowed telemedicine prescribing and mail delivery; and arguments that federal laws prohibiting mailing obscene materials — specifically the 19th-century Comstock Act — apply to mifepristone shipped through the postal system.

The Comstock Act theory is particularly significant because it does not depend on challenging the FDA's approval at all. If courts accepted the argument that mifepristone cannot be mailed under Comstock, the drug could remain FDA-approved while being effectively inaccessible in states that rely on mail delivery to reach patients — which includes most states where abortion is legal but where physical clinic infrastructure is limited. The Biden-era DOJ issued an opinion that Comstock does not apply to mifepristone, but that opinion is not legally binding and is vulnerable to reversal under a different administration.

What Access Actually Looks Like Right Now

The current legal challenge lands in a context where mifepristone access is already fragmented along state lines in a way that the medication's federal approval obscures. In states where abortion is banned or severely restricted, mifepristone is effectively unavailable to residents who need it locally, regardless of what federal law says. In states where abortion is protected, telemedicine prescribing and mail delivery have dramatically expanded access, allowing patients in rural areas or those who cannot take time off work to visit a clinic to obtain the medication from providers licensed in their state.

A successful legal challenge that restricted mifepristone's availability would most acutely harm patients in abortion-access states who are relying on the mail and telemedicine infrastructure that has developed since 2021. Those patients often have the fewest alternatives — they may live far from clinics, lack the financial resources to travel, or have medical circumstances that make in-clinic procedures less appropriate. The people at the protected end of the legal spectrum are paradoxically among the most exposed to practical access loss if federal restrictions on mifepristone's prescribing or distribution are imposed.

The Scientific and Medical Consensus That Keeps Getting Ignored

Every major medical organization that has addressed mifepristone's safety has reached the same conclusion: the drug is safe and effective within its approved parameters. The FDA's own review processes, including the most recent evidence review completed ahead of the 2023 prescribing rule updates, found no basis for restricting access based on safety or efficacy concerns. The adverse event rate for mifepristone is lower than for many commonly prescribed medications that face no legal challenge whatsoever. Legal arguments that FDA approval decisions should be overturned on safety grounds are not supported by the scientific record.

That gap between scientific consensus and legal strategy is not a bug in the anti-mifepristone litigation approach — it is the feature. The goal is not to persuade courts that the drug is medically unsafe. The goal is to find a legal theory, at the right moment, before the right court, that produces the outcome regardless of what the science says. The new challenge represents another attempt to find that combination. Whether it succeeds will depend less on the evidence and more on which courts hear it and which legal theories gain traction in a judiciary that has already demonstrated its willingness to depart from medical consensus on reproductive health questions.